Quick Summary
- BRAFTOVI + cetuximab + FOLFIRI achieved statistically significant and clinically meaningful progression-free survival (PFS) improvement.
- Superior PFS compared to chemotherapy alone (FOLFIRI ± bevacizumab).
- Overall survival (OS) showed clinically meaningful prolonged improvement.
- No new safety signals identified; safety profile consistent with known component profiles.
Pfizer Inc. announced positive progression-free survival (PFS) results from Cohort 3 of the pivotal BREAKWATER trial, demonstrating a statistically significant and clinically meaningful improvement in PFS with BRAFTOVI® (encorafenib) combined with cetuximab (marketed as ERBITUX®) and FOLFIRI chemotherapy in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC).
The triple-combination BRAFTOVI regimen showed superior PFS compared to chemotherapy alone (FOLFIRI with or without bevacizumab) as assessed by blinded independent central review (BICR). Additionally, overall survival (OS) a descriptive secondary endpoint, demonstrated clinically meaningful prolonged improvement with the BRAFTOVI-based approach.
Building on Strong Early Evidence
These progression-free survival findings build upon previously announced positive objective response rate (ORR) data, providing increasingly robust evidence supporting the clinical value of BRAFTOVI as a potential practice-changing treatment for this aggressive cancer subtype. The data underscore the dual benefits of this regimen: meaningful response rates and durable progression-free survival.
These results build on the positive objective response rate data we recently shared, providing further evidence of the meaningful benefit this BRAFTOVI-based targeted approach may offer patients with BRAF V600E,
The combination of significant responses and now improvement in progression-free survival underscores the potential of BRAFTOVI as a potentially practice-changing treatment option for patients and families facing this challenging diagnosis..
Jeff Legos
Clinical Context
BRAF V600E mutations occur in approximately 5-10% of colorectal cancers and historically have been associated with poor prognosis and limited treatment options. Patients with BRAF-mutant mCRC have traditionally faced aggressive disease biology and suboptimal outcomes with standard chemotherapy alone. The emergence of targeted BRAF inhibitor-based combinations represents a significant advancement in the treatment paradigm for this molecularly defined patient population.
Prior to the development of BRAF inhibitor-based regimens, treatment options for patients with BRAF V600E-mutant colorectal cancer were limited to conventional chemotherapy regimens, which demonstrated modest efficacy in this genetically distinct subset. The standard of care involved either traditional chemotherapy doublets or triplets, often with addition of bevacizumab, yielding median progression-free survival durations in the range of 8-10 months. This contrasts sharply with the improved outcomes observed with BRAF-targeted approaches.
Read More: Pfizer’s HYMPAVZI™ Shows Strong Efficacy in Late-Stage Hemophilia Trial
Safety Profile Remains Consistent
At the time of the PFS analysis, the safety profile of BRAFTOVI in combination with cetuximab and FOLFIRI remained consistent with the known safety profiles of each individual regimen component. Notably, no new safety signals were identified during the trial, suggesting that the triple combination is well-tolerated and manageable in a clinical setting.
The absence of unexpected toxicities is particularly important for this patient population, as many will require extended treatment to realize the full benefit of disease control. Maintaining tolerability across treatment courses enables patients to remain compliant with therapy and derive maximum clinical benefit.
MSD Oncology Pipeline Advances With First Phase 3 Data for Intismeran Autogene Plus KEYTRUDA and Sacituzumab Tirumotecan
The Merck oncology pipeline will present first-time Phase 3 results for intismeran autogene plus KEYTRUDA, sacituzumab tirumotecan and KEYTRUDA monotherapy in Madrid from Oct. 23-27, […]
Regeneron Libtayo Dosing Update: CHMP Recommends EU Approval of Every-Six-Week Cemiplimab Regimen Across All Cancer Types
Regeneron says the CHMP has recommended EU approval of an alternative Libtayo dosing schedule: 700 mg every six weeks after an initial 12-week regimen of […]
Lilly Omvoh (mirikizumab-mrkz) Delivers Comprehensive Disease Control in Ulcerative Colitis and Deep Remission in Crohn’s Disease at One Year
New post-hoc analyses from Eli Lilly show Lilly Omvoh (mirikizumab-mrkz) helped 27.7% of ulcerative colitis patients reach comprehensive disease control and 20.4% of Crohn’s disease […]
The BREAKWATER Trial
BREAKWATER is a Phase 3, randomized, active-controlled, open-label, multicenter study evaluating BRAFTOVI combined with cetuximab, either as monotherapy or in combination with chemotherapy (mFOLFOX6 or FOLFIRI), in patients with previously untreated BRAF V600E-mutant mCRC.
Primary Cohort: Patients were randomized to receive BRAFTOVI 300 mg once daily with cetuximab (discontinued after early enrollment evaluation), BRAFTOVI 300 mg once daily with cetuximab and mFOLFOX6 (n=236), or mFOLFOX6, FOLFOXIRI, or CAPOX with or without bevacizumab as control (n=243). The dual primary endpoints for this cohort were ORR and PFS as assessed by BICR, with OS as a key secondary endpoint.
Cohort 3 (Current Results): Patients were randomized to receive BRAFTOVI 300 mg once daily with cetuximab and FOLFIRI (n=73) or FOLFIRI with or without bevacizumab as control (n=74). The primary endpoint was ORR by BICR, with PFS designated as a key secondary endpoint and OS as a secondary endpoint.
The trial’s design reflects a thoughtful approach to understanding BRAFTOVI’s efficacy across different chemotherapy backbones. The inclusion of both mFOLFOX6 and FOLFIRI regimens allows for a comprehensive evaluation of how BRAF inhibition complements distinct chemotherapy platforms, each with different mechanisms of action and toxicity profiles.
Last Modified:
